Huntington's disease is a multi-system disorder. by Mielcarek, M
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=krad20
Download by: [Imperial College London Library] Date: 18 December 2015, At: 07:08
Rare Diseases
ISSN: (Print) 2167-5511 (Online) Journal homepage: http://www.tandfonline.com/loi/krad20
Huntington's disease is a multi-system disorder
Michal Mielcarek
To cite this article: Michal Mielcarek (2015) Huntington's disease is a multi-system disorder,
Rare Diseases, 3:1, e1058464, DOI: 10.1080/21675511.2015.1058464
To link to this article:  http://dx.doi.org/10.1080/21675511.2015.1058464
© 2015 The Author(s). Published with
license by Taylor & Francis Group, LLC©
Michal Mielcarek
Published online: 24 Jul 2015.
Submit your article to this journal 
Article views: 519
View related articles 
View Crossmark data
Huntington’s disease is a multi-system disorder
Michal Mielcarek*
Department of Life Science; Imperial College London; London, UK
Huntington’s disease (HD) is one ofthe most common non-curable rare
diseases and is characterized by choreic
movements, psychiatric symptoms, and
slowly progressive dementia. HD is
inherited as an autosomal dominant dis-
order with complete penetrance.
Although brain pathology has become a
hallmark of HD, there is a critical mass
of new studies suggesting peripheral tis-
sue pathology as an important factor in
disease progression. In particular,
recently published studies about skeletal
muscle malfunction and HD-related car-
diomyopathy in HD mouse models
strongly suggest their important roles,
leading to upcoming preclinical and clin-
ical trials. One might conclude that ther-
apeutic approaches in HD should not be
restricted only to the brain pathology but
instead major efforts should also be made
to understand the cross-talk between dis-
eased tissues like the CNS-Heart or
CNS-skeletal muscle axes.
Introduction
Huntington’s disease (HD) belongs to
a triplet repeat family of disorders and is
caused by the expansion of a CAG trinu-
cleotide within the N-terminal part of the
huntingtin gene (HTT) on chromosome 4
(for a recent review, see).1 This mutation
leads to an extra-long tract of glutamines
within the huntingtin protein (HTT) that
causes the huntingtin protein to aggre-
gate.2 HTT is ubiquitously expressed and
it has been found to be involved in many
critical cellular processes.3,4 In mice, HTT
deletion is embryonically lethal at E 6.5
and leads to defects in all germ layers.5 In
HD, there is a hypothesis suggesting that
small mutant HTT fragments that are
being generated during disease progression
by a proteolysis or mis-splicing process
might account for the tissue pathologies.
A recent study has shown that aberrant
splicing of HTT exon 1 to exon 2 could
be responsible for the production of a
toxic N-terminal fragment that could be
translated into a mutated exon 1 HTT
protein in a CAG-dependent manner.6
Importantly, the short polyadenylated
mRNA that is produced through an
abnormal splicing of exon 1 HTT has
been found to be expressed in many
peripheral tissues like heart, skeletal mus-
cle, kidney, and liver, and expression levels
in these tissues are similar to that in brain
tissue.6 Thus, one might conclude that a
combined (tissue-independent) mecha-
nism is leading to the production of toxic
small HTT fragments that ultimately
causes organ dysfunction. Indeed, in
recent years, multiple studies have indi-
cated a wide array of peripheral organ
pathologies, including severe metabolic
phenotype, weight loss, HD-related car-
diomyopathy, and skeletal muscle wasting
(for recent reviews, see).7,8 Therefore,
despite the fact that HD is still recognized
principally as a neurological disease,
peripheral pathologies, including heart
failure and skeletal muscle malfunction,
might significantly contribute to the over-
all progression of HD.
HD-related cardiomyopathy
There are multiple epidemiological
studies that have demonstrated clearly that
HD patients exhibit a high rate of cardiac
events leading to heart failure (see8 for a
review). In addition, a couple of proof of
concept studies showed that restricted
over-expression of a polyQ peptide or
mutant exon 1 HTT, only in cardiomyo-
cytes, caused a severe cardiac dysfunction
leading to a reduced lifespan in mice9 and
flies,10 respectively. Recent studies in HD
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mouse models showed that HD-related
cardiomyopathy is characterized by early
changes in Connexin-43 localization at
gap junctions, followed by a significant
deregulation of hypertrophic markers and
cardiomyocyte apoptosis in pre-symptom-
atic animals. These changes might lead to
the profound arrhythmia and overall
change in cardiac function that have been
described in symptomatic animals.11
Importantly, these changes were identified
prior to a major brain pathology and cog-
nitive deficiency in HD mouse models.
During disease progression, these early
changes were accompanied by a re-expres-
sion of foetal genes and a moderate degree
of interstitial fibrosis in the symptomatic
animals, resulting in an altered heart phys-
iology and contractile dysfunction. Hence,
one might conclude that some of the early
changes identified in pre-symptomatic
animals might be determined by intrinsic
mutant HTT function.11 However, at this
stage of research, there is still no definitive
answer to the fundamental question of
whether heart failure in HD is caused
exclusively by a widespread pathology of
the Central Nervous System/Sympathetic
nervous system (CNS/SNS) dysfunction
or whether it is due to an intrinsic
unknown function of mutant HTT in the
heart (Figure. 1). Moreover, HD-related
cardiomyopathy is also characterized by a
partial response to the b-adrenergenic
stimulation of HD hearts. A chronic treat-
ment with isoproterenol, which is a potent
b-adrenoreceptor agonist, did not change
the overall gross morphology of the R6/2
murine hearts and some of the hypertro-
phic signals were attenuated in the symp-
tomatic HD animals.12 Interestingly,
HD-related cardiomyopathy is not charac-
terized by mutant HTT aggregates, since a
quantitative methodology failed to iden-
tify aggregate load, even at the end stage
of disease in HD mouse models.11 None-
theless, it is still possible that mutant
HTT forms a specific type of aggregate
that has not been identified due to techni-
cal limitations.
HD-related skeletal muscle atrophy
In HD skeletal muscles, in contrast to
the heart, mutant HTT aggregates are
apparent, but only in HD symptomatic
animals.13 This is accompanied by a pro-
gressive deficiency in the contractile char-
acteristics of the hind limb muscles tibialis
anterior (TA) and extensor digitorum lon-
gus (EDL), followed by a significant loss
of motor units in the R6/2 mouse model
of HD. In addition, these functional mus-
cle impairments are accompanied by an
aberrant deregulation of contractile pro-
tein transcripts and their upstream tran-
scriptional regulators. One may conclude
that these changes result in a significant
reduction in muscle force, due to an
energy imbalance and decreased oxidation
in both fast and slow types of skeletal
muscles.13
Interestingly, HD-related skeletal mus-
cle weakness has been directly correlated
to the re-expression of the HDAC4-
DACH2-myogenin axis.13 These results
clearly identified skeletal muscle dysfunc-
tion as a key pathological feature of HD
(Fig. 1). The function of HDAC4 in skel-
etal muscles has been well described (see14
for a review). Moreover, HDAC4 overex-
pression has been already linked to disease
progression in an amyotrophic lateral scle-
rosis (ALS) mouse model.15 In clinical set-
tings, HDAC4 up-regulation was also
positively correlated with ALS disease pro-
gression.16 Similarly, an amplified level of
HDAC4 has been found in a spinal mus-
cular atrophy (SMA) mouse model and in
SMA patients.17 Since, skeletal muscle
atrophy has been established as a major
symptom of HD, it is expected that
genetic reduction of HDAC4 in skeletal
muscle could be a contributing factor to
the overall improvement of HD pheno-
types.18,19 In summary, recent studies
highlighted a major regulatory role of
HDAC4 in muscle remodelling in neuro-
degenerative diseases.
Conclusions
Recent preclinical studies have revealed
striated muscle pathology as a potential
major component of HD progression. It
is still an open question as to whether
HD-related cardiomyopathy and skeletal
muscle malfunction are secondary events
to CNS/SNS dysfunction or are partially
caused by an intrinsic function of HTT in
these tissues (Fig. 1). Despite this, it has
been clearly shown that improvement of
muscle function leads to a lifespan exten-
sion in HD mouse models.20 Therefore,
this makes striated muscle a valid target
for future therapies and emphasizes
peripheral components as an important
part of HD disease progression. There is
an urgent need to understand the mecha-
nisms leading to HD-related striated mus-
cle pathology, in preclinical and clinical
settings, to be able to shape future thera-
peutic strategies in HD. While CNS dys-
function is a prime target in ongoing
therapeutic studies, it might be necessary
to use more systemic approaches to cure
or delay HD symptoms.
Figure 1. A summary of HD-striated muscle pathology in preclinical settings. CNS (Central Nervous
System); SNS (Sympathetic Nervous System).
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